Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:HSTCOTCMKTS:IMUCNASDAQ:IPSCNYSEAMERICAN:MAIA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSTCHST Global$0.83$0.79$0.23▼$1.11$47.95M-1.191,185 shsN/AIMUCEOM Pharmaceuticals$0.10-10.1%$0.12$0.01▼$0.21$12.95M0.067,961 shs2,036 shsIPSCCentury Therapeutics$0.57+4.9%$0.51$0.34▼$3.46$49.12M1.8493,964 shs1.00 million shsMAIAMAIA Biotechnology$1.75$1.77$1.40▼$5.55$45.78M0.2221,696 shs83,397 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSTCHST Global0.00%0.00%0.00%+1.22%-20.19%IMUCEOM Pharmaceuticals0.00%-35.09%-20.25%-56.19%-64.77%IPSCCentury Therapeutics+0.67%-2.74%-1.18%-10.18%-81.70%MAIAMAIA Biotechnology-1.13%+2.34%-14.63%+2.94%-63.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIPSCCentury Therapeutics2.5347 of 5 stars3.53.00.00.02.21.70.6MAIAMAIA Biotechnology0.8434 of 5 stars0.04.00.00.02.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSTCHST Global 0.00N/AN/AN/AIMUCEOM Pharmaceuticals 0.00N/AN/AN/AIPSCCentury Therapeutics 3.00Buy$4.20636.71% UpsideMAIAMAIA Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMUC, IPSC, HSTC, and MAIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.004/3/2025IPSCCentury TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.003/28/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/24/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $7.003/21/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.003/20/2025IPSCCentury TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.00 ➝ $2.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSTCHST GlobalN/AN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/AN/AIPSCCentury Therapeutics$114.90M0.43N/AN/A$3.06 per share0.19MAIAMAIA BiotechnologyN/AN/AN/AN/A$0.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSTCHST Global-$150K-$0.02N/A∞N/AN/A-13,072.91%-31.66%N/AIMUCEOM Pharmaceuticals-$1.61MN/A0.00∞N/AN/AN/AN/AN/AIPSCCentury Therapeutics-$136.67M-$0.29N/AN/AN/A-4,837.73%-61.66%-31.78%8/14/2025 (Estimated)MAIAMAIA Biotechnology-$19.77M-$1.38N/AN/AN/AN/A-14,708.83%-221.26%8/8/2025 (Estimated)Latest IMUC, IPSC, HSTC, and MAIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IPSCCentury Therapeutics-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million3/19/2025Q4 2024IPSCCentury Therapeutics-$0.45-$0.43+$0.02-$0.43$0.67 million$4.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSTCHST GlobalN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSTCHST GlobalN/A0.250.25IMUCEOM PharmaceuticalsN/AN/AN/AIPSCCentury TherapeuticsN/A10.3910.39MAIAMAIA BiotechnologyN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSTCHST GlobalN/AIMUCEOM PharmaceuticalsN/AIPSCCentury Therapeutics50.20%MAIAMAIA Biotechnology5.65%Insider OwnershipCompanyInsider OwnershipHSTCHST Global65.82%IMUCEOM Pharmaceuticals3.28%IPSCCentury Therapeutics6.80%MAIAMAIA Biotechnology36.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSTCHST Global157.77 million16.33 millionNot OptionableIMUCEOM Pharmaceuticals3126.50 million122.35 millionNot OptionableIPSCCentury Therapeutics17086.16 million79.25 millionOptionableMAIAMAIA Biotechnology926.16 million16.49 millionNot OptionableIMUC, IPSC, HSTC, and MAIA HeadlinesRecent News About These CompaniesMAIA Biotechnology Showcases Promising THIO-101 Trial DataJune 2 at 6:57 AM | tipranks.comMAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer TrialMay 29, 2025 | finance.yahoo.comMAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer TrialMay 27, 2025 | insidermonkey.comCORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000May 27, 2025 | businesswire.comMAIA Biotechnology Increases Authorized Common Stock SharesMay 23, 2025 | tipranks.comWhy MAIA Biotechnology, Inc.’s (MAIA) Stock Is Up 11.93%May 15, 2025 | aaii.comMAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual MeetingMay 15, 2025 | businesswire.comMAIA Biotechnology Announces Director Participation in Recent Private PlacementMay 14, 2025 | businesswire.comMAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.comBest Momentum Stocks to Buy for May 6thMay 6, 2025 | zacks.comNew Strong Buy Stocks for May 6thMay 6, 2025 | zacks.comCORRECTION: MAIA Biotechnology Announces $1.08 Million Private PlacementMay 5, 2025 | businesswire.comMAIA Biotechnology Announces $1.08 Million Private PlacementMay 5, 2025 | businesswire.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest UpdateMay 5, 2025 | marketbeat.comWhy MAIA Biotechnology, Inc.’s (MAIA) Stock Is Down 6.67%April 26, 2025 | aaii.comMAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to ShareholdersApril 1, 2025 | businesswire.comIs MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comMAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should KnowMarch 27, 2025 | zacks.comMAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025March 25, 2025 | businesswire.comMaia Bio touts two advances for its lead cancer drug in developmentMarch 21, 2025 | chicagobusiness.comMAIA Biotechnology Gets USAN Approval For "Ateganosine" As Name For Telomere-Targeting DrugMarch 21, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUC, IPSC, HSTC, and MAIA Company DescriptionsHST Global OTCMKTS:HSTC$0.83 0.00 (0.00%) As of 06/2/2025HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.EOM Pharmaceuticals OTCMKTS:IMUC$0.10 -0.01 (-10.10%) As of 03:09 PM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Century Therapeutics NASDAQ:IPSC$0.57 +0.03 (+4.89%) Closing price 04:00 PM EasternExtended Trading$0.57 0.00 (-0.37%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.MAIA Biotechnology NYSEAMERICAN:MAIA$1.75 0.00 (0.00%) Closing price 04:10 PM EasternExtended Trading$1.76 +0.01 (+0.86%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
